Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Mar 25;10(7):1355.
doi: 10.3390/jcm10071355.

Real-World Performance of a Self-Operated Home Monitoring System for Early Detection of Neovascular Age-Related Macular Degeneration

Allen C Ho  1 , Jeffrey S Heier  2 , Nancy M Holekamp  3 , Richard A Garfinkel  4 , Byron Ladd  5 , Carl C Awh  6 , Rishi P Singh  7 , George E Sanborn  8 , Jennifer H Jacobs  8 , Michael J Elman  9 , Anat Loewenstein  10   11 , David A Eichenbaum  12
Affiliations

Real-World Performance of a Self-Operated Home Monitoring System for Early Detection of Neovascular Age-Related Macular Degeneration

Allen C Ho et al. J Clin Med. .

Abstract

The real-world performance of a home telemonitoring strategy (ForeseeHome AMD Monitoring System®, Notal Vision, Inc.,Manassas VA, USA) was evaluated and compared to the device arm of the AREDS2-HOME study among patients with intermediate AMD (iAMD) who converted to neovascular AMD (nAMD). All patients with confirmed conversion to nAMD who used the home monitoring system from 10/2009 through 9/2018 were identified by Notal Vision Diagnostic Clinic's medical records. Selected outcome variables were evaluated, including visual acuity (VA) at baseline and at conversion, and change in visual acuity (VA) from baseline to time of conversion. In total, 8991 patients performed 3,200,999 tests at a frequency of 5.6 ± 3.2 times/week. The 306 eyes that converted from iAMD to nAMD over the study period (a 2.7% annual rate) were included in the analyses. There was a median (interquartile range) change of -3.0 (0.0-(-10.0)) letters among converted eyes, 81% [95% confidence interval (72-88%)] maintained a VA ≥ 20/40 at the time of conversion, while 69% of the conversion detections were triggered by system alerts. The real-world performance of an at-home testing strategy was similar to that reported for the device arm of the AREDS2-HOME study. The home telemonitoring system can markedly increase early detection of conversion to nAMD.

Keywords: AREDS2-HOME study; ForeseeHome AMD Monitoring System®; neovascular age-related macular degeneration.

PubMed Disclaimer

Conflict of interest statement

Allen C. Ho is a consultant and has received study grants from Notal Vision, Inc.; Jeffrey S. Heier is a consultant for Notal Vision, Inc; Nancy Holekamp is a consultant for Notal Vision, Inc.; Richard A. Garfinkel has no financial disclosures relevant to this publication; Byron Ladd is a consultant for Notal Vision; Carl Awh has an equity interest in Notal Vision, Inc.; Rishi Singh receives research grant funding from Aerie, Apellis, and Graybug; Consultant for Alcon, Bausch and Lomb, Genentech, Regeneron, Novartis, and Zeiss; George E. Sanborn is an employee of Notal Vision, Inc.; Jennifer H. Jacobs is an employee of Notal Vision, Inc.; Michael J. Elman is a consultant and has received study grants from Notal Vision, Inc.; Anat Loewenstein is a consultant for Notal Vision; David A. Eichenbaum is a consultant for Notal Vision, Inc.

Figures

Figure 1
Figure 1
Distribution of the average weekly frequency of testing per eye and per patient.
See this image and copyright information in PMC

References

    1. AREDS-HOME Study Research, Group. Chew E.Y., Clemons T., Bressler S.B., Elman M.J., Danis R.P., Domalpally A., Garfinkel R.A. Randomized trial of the ForeseeHome monitoring device for early detection of neovascular age-related macular degeneration. The HOme Monitoring of the Eye (HOME) study design (HOME Study report number 1) Contemp. Clin. Trials. 2014;37:294–300. doi: 10.1016/j.cct.2014.02.003. - DOI - PMC - PubMed
    1. Ying G.S., Huang J., Maguire M.G., Jaffe G.J., Grunwald J.E., Toth C., Daniel E., Klein M., Pieramici D., Wells J., et al. Baseline predictors for one-year visual outcomes with ranibizumab or bevacizumab for neovascular age-related macular degeneration. Ophthalmology. 2013;120:122–129. doi: 10.1016/j.ophtha.2012.07.042. - DOI - PMC - PubMed
    1. Rao P., Lum F., Wood K., Salman C., Burugapalli B., Hall R., Singh S., Parke D.W., 2nd, Williams G.A. Real-World Vision in Age-Related Macular Degeneration Patients Treated with Single Anti-VEGF Drug Type for 1 Year in the IRIS Registry. Ophthalmology. 2018;125:522–528. doi: 10.1016/j.ophtha.2017.10.010. - DOI - PubMed
    1. Brown D.M., Kaiser P.K., Michels M., Soubrane G., Heier J.S., Kim R.Y., Sy J.P., Schneider S., ANCHOR Study Group Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N. Engl. J. Med. 2006;355:1432–1444. doi: 10.1056/NEJMoa062655. - DOI - PubMed
    1. Heier J.S., Brown D.M., Chong V., Korobelnik J.F., Kaiser P.K., Nguyen Q.D., Kirchhof B., Ho A., Ogura Y., Yancopoulos G.D., et al. Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. Ophthalmology. 2012;119:2537–2548. doi: 10.1016/j.ophtha.2012.09.006. - DOI - PubMed

LinkOut - more resources